U.S. Stock Night Market Movements

Medicus Pharma rose 12.63% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

Stocks with High Trading Volume in the Industry

Moderna fell 0.33% in the night market. Based on recent key news:

1. On June 19, the FDA advisory committee unanimously supported the approval of Moderna's flu vaccine mRNA-1010, believing its benefits outweigh the risks in adults aged 50 and older. This support pushed Moderna's stock price up 4.1% to $64.26;

2. On June 19, analysts rated Moderna as "underweight," believing that five other stocks have more investment value. The negative rating from analysts put pressure on the stock price;

3. On June 19, the FDA's vaccine advisory committee, based on multiple research data, believed that the benefits of Moderna's flu vaccine mRNA-1010 outweigh the risks, with the FDA expected to make a final decision on August 5. This news had a positive impact on the stock price. Competition in the vaccine industry is intensifying, and policy impacts are significant.

MLTX rose 14.78% in the night market. Based on recent key news:

1. On June 22, MoonLake Immunotherapeutics announced the results of its Phase 3 clinical trial for its global project, showing positive progress in the treatment of moderate to severe HS patients. This news drove the stock price up, with significant increases in trading volume. Source: GlobeNewswire

2. On June 22, the company announced it had completed pre-BLA interactions with the FDA and expects to submit its application by the end of September, potentially qualifying for priority review. This progress has enhanced market confidence in the commercial potential of its drugs. Source: GlobeNewswire

3. On June 19, the company's CFO sold some shares, attracting market attention, but it did not have a significant negative impact on the stock price. Source: EDGAR The biotechnology industry has recently performed strongly, with noticeable capital inflows.

Spyre Therapeutics fell 0.38% in the night market. Based on recent key news:

1. On June 18, Spyre Therapeutics' stock price reached a 52-week high of $66.69, up 294% from before. The company's operational and financial performance continues to attract investor attention, driving the stock price up.

2. On June 20, the company is about to announce its Q1 2025 financial report, and investors are closely watching for potential upward revisions in performance, which are expected to have a positive impact on the stock price.

3. On June 20, the market expects the company to announce its Q2 2026 financial report in early August, and any upward revision to the 2026 revenue guidance could further drive the stock price up Recent market volatility has intensified, and attention should be paid to industry dynamics